No. A Malaysian drug registration cannot be held by a company abroad. NPRA is explicit: a foreign company wishing to bring pharmaceutical products into Malaysia must first appoint a local agent - a company registered in Malaysia - to be the holder of the registration certificate, and that agent is then responsible for all matters pertaining to the registration. That holder is the entity NPRA deals with; the manufacturer's name still appears as the manufacturer. What you can keep is the dossier and its ownership, the right to move the registration to a different holder, and the commercial terms around both - provided the agreement is written that way before the application is filed.
This question comes up because in many jurisdictions the answer is different. A manufacturer used to holding its own authorisations reads Malaysia's requirement as a loss of control, and reacts either by handing everything to whichever distributor is closest, or by budgeting for a full local subsidiary. Both reactions are premature. The rule is narrow: it says who must be named as holder. It does not say who owns the dossier, who chooses the distributor, or who can take the registration back.
What the rule actually says
Registration of a medicine in Malaysia is granted to a holder - in NPRA's documents the Product Registration Holder (PRH), the role manufacturers usually call the Marketing Authorisation Holder (MAH). That holder must be a locally incorporated company, registered with the Companies Commission of Malaysia, with a permanent local address. The product is registered in the holder's name and receives a MAL number.
NPRA's own guidance to foreign companies is a single sentence worth keeping: appoint a local agent, registered in Malaysia, to be the holder of the registration certificate - and that agent becomes responsible for all matters pertaining to the registration of the products. "All matters" is not a figure of speech. It covers the submission, correspondence with the regulator, variations, renewals, pharmacovigilance and, since 2026, mandatory shortage reporting.
One clarification, because it causes real confusion: being unable to hold the registration does not make you invisible in the file. The manufacturer is declared as the manufacturer, the manufacturing sites are yours and are inspected as yours, and the name and address of the actual manufacturer must appear on the label. You are not written out of the product. You are written out of the holder field.
What the holder does, and what it does not
The most expensive misunderstanding in Malaysian market entry is treating "holder" and "distributor" as one thing because one company happens to do both.
| Function | Belongs to |
|---|---|
| Named on the registration; NPRA's legal counterparty | Holder (MAH) |
| Submits the dossier, variations and renewals via QUEST | Holder |
| Pharmacovigilance obligations | Holder |
| Mandatory shortage and discontinuation reporting | Holder |
| Physical import, warehousing, cold chain, delivery to customers | Distributor / logistics licence holder |
| Manufacturing, GMP compliance, site inspections | Manufacturer (you) |
| Dossier and its intellectual property | Whoever the agreement says - and it should say you |
Splitting these roles on purpose is a legitimate structure: an independent holder that is not your distributor, and a distributor chosen on commercial merit and replaceable without touching the registration. That is difficult to arrange after the fact and straightforward to arrange before filing.
What still belongs to you
The rule assigns a legal role. It does not transfer your assets. Four things stay with the manufacturer if the paperwork is done properly:
- The dossier and its IP. The holder submits it; ownership is a contractual matter. NPRA's change-of-holder process requires a Letter of Authorisation from the product or dossier owner - which is precisely why documented ownership is what makes a future transfer possible at all.
- The manufacturing sites and their GMP status. Recognised GMP evidence for your sites belongs to you and travels with you, not with the local holder.
- The right to change holder. Malaysia has a defined route for this. It is a transfer, not a re-registration, so the product keeps its MAL number. It requires the dossier owner's Letter of Authorisation, a board resolution from the outgoing holder consenting to the change, a statement of acceptance from the incoming holder, and the incoming holder's SSM company documents. Practical constraint to plan around: the registration being transferred must have at least six months of validity remaining.
- Commercial control of your own product. Pricing, supply volumes, which markets you serve and on what terms are contract questions, not regulatory ones.
Note the asymmetry hiding in that list: the outgoing holder's board resolution consenting to the change is required. So while the transfer route exists, it is not unilateral. A holder that does not wish to let go is an obstacle the regulation does not remove for you - which is exactly why the terms are worth negotiating while you still have something the other side wants. Our article on changing the MAH in Malaysia walks through that process in detail.
Which structure to choose
There are three realistic holders: your own Malaysian subsidiary, your distributor, or an independent MAH. The trade-off is control against speed and fixed cost - a subsidiary gives the most control and costs the most; distributor-as-holder is fastest and carries the most lock-in, because your regulatory position ends up inside your commercial counterparty; an independent holder gives local legal presence without your own entity and keeps distribution a separate, replaceable contract. We compare the three side by side, with costs and decision criteria, in what an MAH does and how to appoint one, and cover the lock-in case specifically in distributor as your MAH.
The rest of this article deals with the question those two do not: once someone else is the named holder, what can they do without asking you?
What your holder cannot do without you
This is the practical measure of control, and it is more favourable to the manufacturer than the "you cannot hold it" rule suggests. Several acts depend on documents only the manufacturer or dossier owner can produce:
| Action | Needs the manufacturer / dossier owner? |
|---|---|
| Transfer the registration to a different holder | Yes - Letter of Authorisation from the product or dossier owner |
| Submit the dossier at all | Yes - the dossier and the manufacturer's authorisation to use it |
| Rely on your GMP status and manufacturing sites | Yes - the evidence belongs to your sites |
| Keep marketing the product if you stop supplying it | No - but a discontinuation then becomes a reportable event in their name |
| Report a shortage, propose an impact rating, state a public reason | No - the holder files this, which is why the reporting protocol belongs in your agreement |
| Refuse to cooperate with a transfer you want | Effectively yes, unless contracted otherwise - the outgoing holder's board resolution is required |
Read the table as two columns of leverage. Yours is the dossier and the sites: without them the holder has nothing to file and nothing to defend. Theirs is the named position and, from 2026, the voice that speaks to the regulator about your supply. Contracts are what convert that standoff into something predictable - which is the whole argument for settling terms before the first filing rather than at the first dispute.
A duty that changed in 2026
One reason the choice of holder deserves more attention now than it did two years ago: since 1 July 2026 reporting medicine shortages and discontinuations to NPRA is mandatory, with notice expected at least six months in advance, and that duty falls on the registration holder. Enforcement escalates to formal warning letters with two-day response deadlines, and to financial penalties.
For a foreign manufacturer this means a supply hiccup at your plant becomes a filing obligation in Malaysia, executed by someone else, published in a public database under their name and your product's - with a stated reason. Whoever holds your registration now speaks for your supply chain on the public record. The full mechanics are in our guide to Malaysia's medicine shortage reporting rules.
Getting it right before you file
Whichever structure you choose, five points belong in the agreement before the application goes in:
- Dossier ownership stated explicitly as the manufacturer's, with the Letter of Authorisation mechanism acknowledged.
- Transfer rights: the holder's obligation to consent to and cooperate with a change of holder, including providing the board resolution, on defined triggers.
- Termination and what happens to the registration - including timing, given the six-month remaining-validity constraint.
- Reporting protocol: who notifies whom internally about supply risk, on what timeline, and who approves the public wording of a shortage report.
- Separation of distribution: whether the holder also distributes, and whether you can appoint or change distributors independently.
RHMI is a Malaysian company that acts as an independent Marketing Authorisation Holder: we hold the registration locally so you do not need your own entity, while your dossier ownership and transfer rights stay documented as yours from the first filing. Because we are not the party selling your product into the market, choosing or changing a distributor never puts your registration at risk.
Frequently asked questions
Can a foreign manufacturer hold a drug registration in Malaysia?
No. The holder must be a company incorporated in Malaysia. NPRA directs foreign companies to appoint a local agent, registered in Malaysia, as the holder of the registration certificate; that agent is then responsible for all matters pertaining to the registration.
Does that mean I lose control of my product?
Not if the agreement is written properly. The registration certificate sits with the local holder, but the dossier and its IP remain yours, and NPRA's change-of-holder route requires a Letter of Authorisation from the dossier owner - making your consent the gate for any transfer.
Can I set up my own Malaysian company to be the holder?
Yes. A locally incorporated subsidiary can hold the registration. It gives the most control and costs the most: incorporation, licences, staffing, and all the regulatory duties including shortage reporting sit with you.
What is the difference between the holder and the distributor?
The holder is the legal owner of the registration and NPRA's counterparty for variations, renewals, pharmacovigilance and shortage reporting. The distributor imports, stores and delivers. One company can do both - but they are separate roles, and separating them deliberately protects your registration when commercial arrangements change.
Can the registration be moved to another holder later?
Yes, via NPRA's change of product registration holder process. It is a transfer, so the MAL number is kept. It needs a Letter of Authorisation from the dossier owner, a board resolution from the outgoing holder, a statement of acceptance from the incoming holder and their SSM documents; the registration must have at least six months of validity remaining.
Who reports a medicine shortage if the holder is not the manufacturer?
The local holder. Since 1 July 2026 shortage and discontinuation reporting is mandatory with at least six months' advance notice, and the obligation belongs to the holder, not the foreign manufacturer.
You might also find useful
- Marketing Authorisation Holder (MAH) in Malaysia: What It Is and How to Appoint One
- Malaysia's Medicine Shortage Reporting Rules (2026): What Every MAH Must Now Do
- Sources:
- NPRA - FAQ, Product Registration (appointment of a local agent as holder of the registration certificate): npra.gov.my
- NPRA - Drug Registration Guidance Document (DRGD): npra.gov.my
- NPRA - DRGD Appendix 31, Change of Product Registration Holder (LOA, board resolution, statement of acceptance, remaining validity): npra.gov.my (PDF)
- MOH Malaysia - Guideline on Reporting of Medicine Shortage and Discontinuation in Malaysia, August 2025: npra.gov.my (PDF)
- Editorial note: This article is general business and regulatory information for manufacturers evaluating Malaysia. It is not legal or regulatory advice. Confirm current requirements, documentation and fees against NPRA's official guidance before acting.